A First-in-Human Dose Escalation and Expansion Study to Evaluate Intratumoral Administration of SAR441000 as Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors

Clinical trial NCT03871348 · TERMINATED

Trial details

NCT number: NCT03871348
Sponsor: Sanofi
Status: TERMINATED
Phase: Phase 1
Study type: INTERVENTIONAL

Metastatic Neoplasm

Start date: 2019-01-03
Primary completion: 2022-07-25
Enrollment: 77

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.